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Multiresistant Acinetobacter infections: a role for sulbactam
combinations in overcoming an emerging worldwide problem
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Recent studies have highlighted the emergence of infections involving multiresistant
Acinetobacter clinical isolates. Sulbactam offers direct antimicrobial activity against
Acinetobacter species. Accordingly, co-administration of sulbactam with ampicillin or
cefoperazone offers the potential of effective empirical therapy against Acinetobacter and
other bacteria such as Enterobacteriaceae in institutions in which they are susceptible.
Many in vitro studies have indicated that Acinetobacter remains fully susceptible to
ampicillin–sulbactam or cefoperazone–sulbactam. Furthermore, ampicillin–sulbactam
has proven clinically effective and well tolerated in the treatment of severe acinetobacter
infections, including bacteremia. Therefore, ampicillin–sulbactam is a sensible option for
the treatment of life-threatening acinetobacter infections.
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I N T R O D U C T I O N
With the development of modern infection-mon-
itoring programs, the clinical importance of Aci-
netobacter species, particularly Acinetobacter
baumannii, has been determined. These species
are now known to be responsible for a wide range
of nosocomial infections, including bacteremia,
secondary meningitis and urinary tract infections,
and to play an important role as infective agents in
late-onset nosocomial pneumonia among inten-
sive care unit (ICU) patients. Acinetobacter species
are ubiquitous opportunistic pathogens that colo-
nize the skin of up to 25% of healthy adults [1], and
are among the most common Gram-negative
organisms isolated from the skin of hospital per-
sonnel [2]. They are also frequently grown from
sputum, urine and feces [3].
In the USA, an audit of infections among adult
and pediatric ICU patients during the period
1987–1996 [4], performed by the National Noso-
comial Infections Surveillance System, reported
3447 nosocomial acinetobacter infections during
5 596 156 patient-days, the average rates of infec-
tion being significantly higher during the summer
than in the winter. Elsewhere, other studies have
confirmed the association of Acinetobacter species
with nosocomial infections [1,5–7], and have high-
lighted sudden increases in the regional incidence
of colonization and infection [8].
Acinetobacter infections are most frequently
associated with the use of a ventilator or other
invasive device [9], and risk factors include neuro-
surgery, acute respiratory distress syndrome, and
head trauma [10]. Given the increasing availability
of intensive care facilities and more sophisticated
invasive clinical procedures, the prevalence of
acinetobacter infections is likely to increase.
Accordingly, it is appropriate to re-evaluate the
clinical role of established antibiotics in treating
these infections. This review considers the in vitro
activity and clinical efficacy and safety of two
sulbactam-based b-lactam/b-lactamase inihibitor
combinations, ampicillin–sulbactam and cefoper-
azone–sulbactam.
E X T E N T O F R E S I S T A N C E I N
A C I N E T O B A C T E R
The increasing, and sometimes inappropriate,
administration of antibacterial agents [11],
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together with the growing use of invasive diag-
nostic and therapeutic procedures, has contribu-
ted to the development of resistant bacterial
species among hospitalized patients, especially
those at high risk (i.e. ICU patients).
An important feature of Acinetobacter species,
and A. baumannii in particular, is their intrinsic
resistance to multiple antibiotics. Recently
reported surveillance surveys have demonstrated
high rates of resistance to aminoglycosides, cepha-
losporins, quinolones, penicillins, monobactams,
and imipenem, often in excess of 50%, among
clinical isolates of Acinetobacter [7,12–14]. For
example, of 85 strains of Acinetobacter species col-
lected at one hospital in Thailand in 1996–1997,
50% were resistant to cefoperazone, tetracycline
and co-trimoxazole, 20–50% to piperacillin, cipro-
floxacin, ceftazidime, cefotaxime, doxycycline,
amikacin and ofloxacin, and 10–20% to piperacil-
lin–tazobactam, levofloxacin, cefepime, sparfloxa-
cin and minocycline [14]. Other studies have
reported imipenem resistance among Acinetobacter
strains [5,6,15].
Infection due to highly resistant Acinetobacter
strains can lead to treatment failure, and is asso-
ciated with an increased risk of death [16]. Even if
death is avoided by prescribing alternative med-
ication, an extended stay within the ICU is
required, and the total length of stay in hospital
will be longer. Thus, infection by highly resistant
Acinetobacter can lead to a dramatic increase in the
overall cost of care [17].
M E C H A N I S M S O F A N T I B I O T I C
R E S I S T A N C E I N A C I N E T O B A C T E R
The full extent of the mechanisms of resistance of
Acinetobacter species to b-lactams remains unclear
[18]. One study isolated the b-lactamase TEM 1
from 16% of 54 clinical isolates of A. baumannii, and
cephalosporinase from 98% of the strains [19].
Other resistance mechanisms that were detected
included three classes of aminoglycoside-modify-
ing enzymes, isolated from up to 28% of strains.
However, the presence of TEM 1 and cephalospor-
inase cannot explain the resistance of Acinetobacter
strains to either extended-spectrum cephalospor-
ins or carbapenems.
The isolation of a carbapenase from Acinetobacter
strains that lack any alteration in the outer mem-
brane probably explains the resistance of Acineto-
bacter to imipenem [15]. Another study suggests
that the antibiotic resistance of Acinetobacter strains
is attributable to the expression of altered penicil-
lin-binding proteins (PBPs) [20]. The outer-mem-
brane permeability of Acinetobacter species to
b-lactams has been studied and shown to be 1–3%
of that of Escherichia coli. This decreased perme-
ability is probably due to the presence of the small
number of low-molecular-mass porins [21].
Regardless of the mechanisms involved, the
high incidence of reduced antibiotic sensitivity
among Acinetobacter strains isolated from ICU
patients demonstrates that more effective strate-
gies are needed to control the selection and spread
of resistant organisms, and that alternative safe
therapeutic agents are required.
R O L E O F S U L B A C T A M I N
O V E R C O M I N G R E S I S T A N C E
Co-administration of a b-lactamase inhibitor with
the b-lactam antiobiotic has proven successful in
overcoming b-lactamase-mediated resistance [22].
b-Lactamase inhibitors possess a b-lactam struc-
ture but only limited antimicrobial activity [23].
Their major value is in blocking the catalytic activ-
ity of b-lactamases against b-lactam antibiotics by
binding irreversibly to the active sites of enzymes
produced by the bacteria. The anti-b-lactamase
spectrum of these inhibitors includes plasmid-
mediated transferable enzymes and various
extended-spectrum enzymes [23]. There are three
b-lactamase inhibitors in clinical use: sulbactam,
tazobactam, and clavulanic acid [22].
Sulbactam is a synthetic b-lactam molecule, with
structural, chemical and pharmacokinetic proper-
ties similar to those of aminopenicillins. A feature
that distinguishes sulbactam from other available
b-lactamase inhibitors is its direct antimicrobial
activity against Bacteroides fragilis and Acinetobacter
species, organisms against which most cephalos-
porins display little or no activity [23]. Binding of
sulbactam to PBP 2 of these organisms imparts
intrinsic antibacterial activity [24].
M I C R O B I O L O G I C A L A C T I V I T Y O F
A M P I C I L L I N – S U L B A C T A M A N D
C E F O P E R A Z O N E – S U L B A C T A M
There are two sulbactam combinations in clinical
use: ampicillin–sulbactam and cefoperazone–sul-
bactam. The combination of ampicillin and sul-
bactam is available as both parenteral (intravenous
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or intramuscular) and oral formulations (as the
mutual prodrug sultamicillin). By contrast, cefo-
perazone–sulbactam is available as a parenteral
(intravenous or intramuscular) formulation only
[22].
The findings of studies that have investigated
the in vitro susceptibility of Acinetobacter species to
ampicillin–sulbactam and cefoperazone–sulbac-
tam reveal that the susceptibility rates vary widely
geographically (nationally and regionally) and
with time. One explanation for this is variation
in the methods of susceptibility testing and in the
breakpoints used to determine sensitivity. Larger,
multicenter, international studies tend to standar-
dize the methods used and provide more valuable
information on the true resistance profile of Aci-
netobacter species. Nonetheless, smaller regional
studies remain important for identifying the emer-
gence of localized acinetobacter multidrug resis-
tance. The in vitro activity data on combinations
with sulbactam probably result from the fact that
in most countries sulbactam is not available alone.
It would appear, however, that acinetobacter sus-
ceptibility is due mainly to sulbactam.
Ampicillin–sulbactam
In vitro susceptibility studies in North America,
South America, Europe, and Asia, involving clin-
ical isolates collected during 1988–1999, have
reported a wide variety of susceptibility rates
for ampicillin–sulbactam as well as other antibio-
tics (Table 1). Most studies use National Commit-
tee for Clinical Laboratory Standards (NCCLS)
criteria, in which a rate of 2 : 1 for ampicillin–
sulbactam is used for agar dilution or a disk with
Table 1 In vitro susceptibility of Acinetobacter species to ampicillin–sulbactam
Study Country
Collection date
(no. of isolates) Ampicillin–sulbactam Comparators (% strains)
North America
Marques et al.
1997 [57]
USA 1994 (n¼ 14) MIC50: 8/4; MIC90: 16/8 MDR isolates:
imipenem, 100%;
amikacin, 21%;
piperacillin/tazobactam, 14%;
others, 0.1%
Urban et al.
1993 [32]
USA 1988–1989 (n¼ 20) MIC90: 8/4 MIC90:
ciprofloxacin, >4;
co-trimoxazole, >8/152;
gentamicin, >8;
imipenem, 16;
amikacin, >16;
cefotaxime, >16;
amoxicillin–clavulanic
acid, >16/8;
piperacillin–tazobactam, 64/8;
ticarcillin–clavulanic acid, >64
Murray et al.
1994 [29]
USA NS (n¼ 784) 81.4%a
MIC50: 4/2; MIC90: 32/16
Imipenem, 96.4%;
ticarcillin–clavulanic acid, 74.4%;
piperacillin–tazobactam, 66.8%;
ceftazidine, 64.7%;
ciprofloxacin, 63.4%;
piperacillin, 54.2%;
ceftriaxone, 49.4%
Murray et al.
1993 [28]
USA NS (n¼ 25) 100%a
MIC50: 1/1; MIC90: 2/2
Imipenem, 100%;
ceftazidime, 100%;
ceftizoxime, 100%;
ticarcillin–clavulanic acid, 96%;
cefotaxime, 84%;
ceftriaxone, 76%;
cefoperazone, 32%;
cefotetan 12%
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10 mg/10 mg [25]. However, some studies do not
even mention the susceptibility criteria used.
Table 1 includes only studies in which susceptibil-
ity criteria were well defined and minimal inhibi-
tory concentrations for sulbactam were obtained.
Most strains of Acinetobacter species remain fully
susceptible to ampicillin–sulbactam. In particular,
recent studies in Brazil and Italy have confirmed
high rates of susceptibility of Acinetobacter species
to ampicillin–sulbactam [26,27]. Among the larger,
multicenter studies, reported susceptibility rates
are in the range 81–100% [26,28,29]. Currently
available susceptibility data reveal no clear geo-
graphic trend in the global susceptibility of Acine-
tobacter species to ampicillin–sulbactam (Table 1).
A few studies have compared temporal changes in
susceptibility rates within regions. For example,
Garcia-Arata et al. [30] in Spain traced the emer-
gence of resistance among Acinetobacter species
over a 5-year period (1990–1994), and detected
Table 1 continued
Study Country
Collection date
(no. of isolates) Ampicillin–sulbactam Comparators (% strains)
South America
Mendes et al.
1998 [26]
Brazil 1994 (n¼ 9) 92%a
MIC90: 8/4
Co-trimoxazole, 52%;
ampicillin, 25%;
cephalothin, 15–20%
Europe
Tascini et al.
1998 [27]
Italy NS (n¼ 5) 100%a
MIC90: 8/4
Polymixin B, 100%;
rifampicin, 0%
Garcia-Arata
et al. 1996 [30]
Spain 1990–1994 (n¼ 177) 97%a
MIC50: 4/2; MIC90: 8/4
Carbapenems, 99%;
amikacin, 94%;
piperacillin–tazobactam, 60%;
ceftazidime, 25%;
ticarcillin, 24%;
piperacillin, 18.1%
Douboyas et al.
1994 [31]
Greece 1992–1993 (n¼ 219) 82%a
MIC50: 8/4; MIC90> 32/16
Amikacin, 21%;
ciprofloxacin, 16%;
ceftazidime, 10%;
piperacillin, 10%
Asia
Shi et al.
1996 [58]
Taiwan NS (n¼ 248) 66.5%a
MIC50: 2/1; MIC90: 32/16
Imipenem, 98.7%;
meropenem, 98.7%;
ciprofloxacin, 96.8%;
amikacin, 72.2%;
cefipime, 67.7%;
ceftazidime, 58.5%;
piperacillin–tazobactam, 55.6%;
amoxicillin–clavulanic acid,
30.2%;
piperacillin, 28.6%
Cheng et al.
1993 [59]
Hong Kong 1986–1990 (n¼ 48) MIC50: 1/1
MIC90: 16/16
MIC90:
amikacin, 2;
amoxicillin–clavulanic acid, 16;
ceftazidime, 16;
cefpirome, 32;
gentamicin, 32;
cefuroxime, >128
NS, not specified; MDR, multiresistant (resistant to two or more aminoglycosides and two or more extended-spectrum
penicillins); MIC, minimal inhibitory concentration, in mg/L; MIC50, MIC for 50% of isolates tested; MIC90, MIC for 90% of
isolates tested. aMIC determination and interpretation based on National Committee for Clinical Laboratory Standards
(NCCLS) criteria (susceptible if MIC 8/4 mg/L).
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an increase in resistance to ticarcillin, piperacillin–
tazobactam, ceftazidime, amikacin, and ofloxacin,
but not ampicillin–sulbactam. A study showed
that Acinetobacter species remain more susceptible
to ampicillin–sulbactam than to other b-lactam/
b-lactamase inhibitor combinations [29], but
another study demonstrated superior activity
for ticarcillin–clavulanic acid [28]. Imipenem
and meropenem generally remain more active
than ampicillin–sulbactam [28,29], although some
studies have shown ampicillin–sulbactam to be
superior [31,32]. Ampicillin–sulbactam has consis-
tently been shown to be more active in vitro than a
wide variety of other, non-combination b-lactam
agents, including many cephalosporins [28,29,31–
33]. Furthermore, ampicillin–sulbactam has been
demonstrated to be more effective in vitro than
ciprofloxacin and ofloxacin [31,33] and gentamicin
[32,33].
Acinetobacter is not a homogeneous genus, and
different genospecies may present different sus-
ceptibility patterns [34]. In one study, A. baumannii
was more resistant to ampicillin–sulbactam, with
an MIC50 and MIC90 of 4/2 and 32/16 mg/L,
respectively, compared with 2/1 and 4/2 for other
genospecies [35].
Cefoperazone–sulbactam
Studies in North America, South America, Europe
and Asia have also investigated the in vitro activity
of cefoperazone–sulbactam, and have shown it to
be superior to that of cefoperazone alone against
clinical isolates of many Gram-negative bacilli, but
particularly against Acinetobacter species in which
activity is due to sulbactam alone [32,36–39]
(Table 2). One of the most important problems
with many studies comprises the criteria used to
define susceptibility. For the combination cefoper-
azone–sulbactam, there is no NCCLS standard for
sulbactam concentration for agar dilution or disk
diffusion tests, and interpretations usually take
into account MICs of cefoperazone (Table 2). Some
studies use ratios of 2 : 1, but others do not even
mention the sulbactam concentration used. Table 2
includes only the studies in which the criteria of
interpretation of susceptibility were defined and
MICs for sulbactam were obtained.
Few studies have evaluated trends in the resis-
tance of Gram-negative bacilli, including Acineto-
bacter species, to cefoperazone–sulbactam. In
Japan, comparison of 1999 susceptibility data with
those of 1998 demonstrated continued in vitro
activity of broad-spectrum b-lactams, including
cefoperazone–sulbactam [40], and the rapid emer-
gence of new or novel resistance was not observed.
The greatest changes observed were in the rates of
resistance to cefepime (from 7.0% to 10.0%) and
cefpirome (from 12.1% to 16.5%).
In vitro studies have shown that cefoperazone–
sulbactam is more active than a variety of indivi-
dual b-lactam agents against Acinetobacter species
[41], and only imipenem has demonstrated in vitro
activity superior to that of cefoperazone–sulbac-
tam [42].
C L I N I C A L E F F I C A C Y A N D
T O L E R A B I L I T Y O F
A M P I C I L L I N – S U L B A C T A M
Efficacy
There have not been any randomized clinical trials
published to date, and all the data are based on
uncontrolled studies. An experimental study of
A. baumannii endocarditis in rabbits and pneumo-
nia in mice suggested that the activity of sulbactam
is time dependent and similar to that of imipenem
against susceptible strains [43]. Clinical studies
have demonstrated the efficacy of ampicillin–sul-
bactam in the treatment of severe multiresistant A.
baumannii infections [44,45], including meningitis
[33] and bacteremia [46], and infections due to
imipenem-resistant A. calcoaceticus [32].
Several studies have evaluated the clinical effi-
cacy of ampicillin–sulbactam specifically against
acinetobacter infections. In 1996–1997, our group
investigated the efficacy of ampicillin–sulbactam
in treating nosocomial infections due to multire-
sistant A. baumannii (MRAB; resistant to anti-
pseudomonal penicillins and cephalosporins,
imipenem, quinolones and aminoglycosides)
[44]. In all, 23 patients (aged 8–79 years) were
treated with intravenous ampicillin–sulbactam
3–18 g/day. All patients had underlying medical
conditions and APACHE II scores in the range 3–
28 (mean 16.4). The infections included pneumo-
nia (35%), bacteremia (26%), surgical site infec-
tions (13%), meningitis (9%), peritonitis (9%),
urinary tract infections (4%), and sinusitis (4%).
Cure or marked improvement was observed in 13
of 23 (56.5%) patients. Six clinical failures included
two cases of meningitis. The remaining patients
were non-evaluable.
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At around the same time, Corbella et al. [45]
evaluated ampicillin–sulbactam (2 g/1 g three
times daily) compared with sulbactam alone (1 g
three times daily) in the treatment of non-life-
threatening MRAB. Cure or marked improvement
within 72 h of the start of therapy was seen in 22 of
23 (95.6%) evaluable ampicillin–sulbactam-treated
patients and 17 of 18 (94.4%) evaluable sulbactam-
treated patients. These data illustrate that the clin-
ical activity of the ampicillin–sulbactam combina-
tion is attributable to the antimicrobial activity of
the sulbactam component, and that sulbactam
alone may be clinically effective against MRAB
infections. In some European countries, such as
Spain, France and Germany, sulbactam is available
not in combination.
A study by Jime´nez-Mejias et al. [33] confirmed
the clinical effectiveness of ampicillin–sulbactam
in treating A. baumannii meningitis. Eight patients
yielded isolates resistant to cephalosporins, cipro-
floxacin and gentamicin, and nearly all (7/8) iso-
lates were resistant to imipenem. All patients
received intravenous ampicillin–sulbactam 2 g/
1 g three or four times daily. Cure was observed
in six of eight (75%) cases. The blood–brain barrier
permeability to sulbactam is poor in the absence
of inflammation [47], and may lead to treatment
failures.
Table 2 In vitro susceptibility of Acinetobacter species to cefoperazone–sulbactam
Study Country
Collection date
(no. of isolates)
Cefoperazone/
sulbactam
Comparators
(% strains)
North America
Jones et al.
1985 [37]
USA NS (n¼ 15) MIC50: 1 and MIC90: 2 for
sulbactam alone
MIC50 cefoperazone alone: 64
Eliopoulos et al.
1989 [38]
USA 1987–1988
(n¼ 84)
MIC50: 8 and MIC90: 16
for sulbactam alone
MIC50 cefoperazone alone: 64
MIC90 cefoperazone alone>128
Knapp et al.
1989 [39]
USA NS (n¼ 21) MIC50: 1/0.5; MIC90: 2/1 MIC50 cefoperazone alone: 16
MIC90 cefoperazone alone: 32
South America
Jones et al.
1997 [42]
Colombia NS (n¼ 72) 83.3%a
MIC50: 2/1; MIC90: 48/24
Imipenem, 95.8%;
cefepime, 86.1%;
ceftazidime, 70.8%;
cefotaxime, 40.3%;
aztreonam, 29.6%
Europe
Pfaller et al.
1999 [60]
Turkey 1997 (n¼ 80) 73.8%a
MIC50: 6/3; MIC90: 64/32
Imipenem, 85.0%;
cefepime, 43.8%;
ticarcillin–clavulanic acid, 29.3%;
ceftazidime, 23.8%;
cefotaxime, 18.8%;
aztreonam, 17.2%
Asia
Lim and Cheong
1995 [36]
Malaysia 1994 (n¼ 21) 21 cefoperazone-resistant
strains (MIC> 32 mg/L),
MIC50: 8 and MIC90: 32
for sulbactam
Yamaguchi et al.
1999 [41]
Japan 1997 (n¼ 199) 99.5%a
MIC50: 2/1; MIC90: 4/2
Imipenem, 97.0%;
cefepime, 89.4%;
ceftazidime, 84.4%;
cefpirome, 83.4%;
piperacillin, 28.0%
NS, not specified; MIC, minimal inhibitory concentration, in mg/L; MIC50, MIC for 50% of isolates tested; MIC90, MIC for
90% of isolates tested. aMIC determination and interpretation based on National Committee for Clinical Laboratory
Standards (NCCLS) criteria for cefoperazone (susceptible if MIC 16 mg/L) [25].
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In the case of A. baumannii bacteremia, Cisneros
et al. [46] treated eight patients with ampicillin–
sulbactam and 42 with imipenem, and observed
response rates of 83.0% and 87.5%, respectively.
Another study, by Urban et al. [32], recorded
improvement in nine of 10 (90%) patients with
imipenem-resistant A. calcoaceticus infections trea-
ted with ampicillin–sulbactam. Similarly, an era-
dication rate of 80% was recorded in nine patients
with urinary tract infections due to A. calcoaceticus
treated with ampicillin–sulbactam [48]. Most stu-
dies used intravenous treatment, as the infections
treated were severe, with daily doses ranging from
1 to 6 g of sulbactam. The oral form may be useful
as subsequent treatment.
Tolerability
A large body of clinical evidence has shown that
ampicillin and cefoperazone offer favorable toler-
ability profiles in the clinical setting. Clinical stu-
dies have also shown that ampicillin–sulbactam
[33,44,45,49] presents virtually no side-effects, that
cefoperazone–sulbactam [50–52] is well tolerated,
and that the addition of sulbactam does not com-
promise the safety of the b-lactam agents.
W E I G H I N G U P T H E E V I D E N C E
Prior use of broad-spectrum antibiotics, the use
of a urinary tract catheter, prior surgery and
mechanical ventilation are significant risk factors
for nosocomial sepsis caused by A. baumannii.
Furthermore, as a focus of infection, multiresistant
A. baumannii contributes to increased mortality,
intensifying the need for appropriate management
of patients, and the careful selection of antibacter-
ial therapy [44].
An in vitro microbial activity spectrum that
includes Acinetobacter species, proven clinical effi-
cacy when given intravenously or intramuscularly
to patients with moderate-to-severe infections,
and a favorable tolerability profile, together sug-
gest that ampicillin–sulbactam is a sensible option
for the treatment of acinetobacter infections, and
sulbactam alone may be used where available.
Several studies have demonstrated clinical efficacy
against Acinetobacter strains resistant to other com-
monly used antibiotics, including imipenem.
In recent years, the only other antibacterial agent
that has consistently been shown to be active
against Acinetobacter is colistin [53,54]. Colistin
can therefore be considered a useful option against
multiresistant infections, despite its potential
toxicity (kidney damage, neurotoxicity, and neu-
romuscular blockade) [55]. The orally adminis-
tered mutual prodrug sultamicillin possesses a
pharmacokinetic/pharmacodynamic profile simi-
lar to that of parenteral ampicillin–sulbactam, and
this allows the subsequent treatment of patients
with an oral formulation of already proven efficacy
and tolerability, and avoids the potentially adverse
clinical and financial impacts of prolonged par-
enteral therapy [56].
In the case of cefoperazone–sulbactam, in vitro
studies have demonstrated antimicrobial activity
against most strains of Acinetobacter species, with
only imipenem offering superior activity. Further
studies are required to confirm the efficacy of
cefoperazone–sulbactam against Acinetobacter in
the clinical setting. Nonetheless, several clinical
studies with sulbactam alone or in combination
have provided evidence of eradication of clinical
Acinetobacter isolates and good clinical response
rates among patients with acinetobacter infections.
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